18 and older, any sex, with Vertigo or Dizziness. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
VRT vs. ED SOC Six-Category Diagnosis Accuracy (Primary Analysis-eligible Participants, Two-arm Comparison)Primary· 30-day follow-up time point
Total diagnosis accuracy VRT vs. ED SOC using 30-day adjudicated final diagnoses categorized in one of six diagnosis categories (3 peripheral, 1 central, 1 medical/other, 1 non-diagnosis). VRT diagnoses were based on automated interpretation of ED index VOG tests in the context of structured medical history information and examination findings from the ED index visit (clinically supervised for safety), while ED SOC diagnoses were based on all clinical information from the ED index visit, including neuroimaging and consultations. Final diagnoses were based on ED index visit, 1-week, and 30-day
Participants with a correct ED index visit diagnosis
Group
Value
95% CI
VOG-guided Rapid Triage (VRT) Care
24
Standard of Care (SOC) Care
18
Participants with an incorrect ED index visit diagnosis
Group
Value
95% CI
VOG-guided Rapid Triage (VRT) Care
33
Standard of Care (SOC) Care
38
VRT vs. ED SOC Total Diagnostic Utilization Costs at the ED Index Visit (Primary Analysis-eligible Participants, Two-arm Comparison)Primary· 30-day follow-up time point
Total US dollar costs VRT vs. ED SOC for diagnostic tests and consultations obtained during the ED index visit and associated hospital admission (for those admitted at the index visit). For the VRT arm, this does not include costs of safety MRIs required by the institutional review board (IRB)-approved protocol or any tests ordered "off protocol" by ED physicians (i.e., it represents VRT-recommended utilization-based costs); however, it does include tests, consultations, or admissions ordered "on protocol" by consultants or ED physicians in the VRT "equivocal" diagnosis pathway. For the SOC ar
Group
Value
95% CI
VOG-guided Rapid Triage (VRT) Care
3007.1
2367.9 – 3646.3
Standard of Care (SOC) Care
3599.0
2986.1 – 4211.8
Participants With Short-Term Prespecified Medical Event(s) of Interest (PMEIs) After a Correct vs. Incorrect Diagnosis (Primary Analysis-eligible Participants, One-arm Comparison [SOC Arm Only])Primary· 1-week follow-up time point
PMEIs included ED revisits, falls, vascular events, and test or treatment complications. PMEIs occurring between the ED index visit disposition and 1-week follow-up visit (after which the two arms joined the same diagnostic pathway) were considered. Events diagnosed at ED index visit were not counted. Events newly diagnosed at 1-week follow-up or in the interval prior to 1-week follow-up were counted, regardless of relatedness to ED index dizziness symptoms, with the exception of test or treatment complications, which were required to be related directly or indirectly to the dizziness symptoms
Participants with zero PMEIs
Group
Value
95% CI
Standard of Care (SOC) Care Trial Arm Participants With a Correct ED SOC Diagnosis
17
Standard of Care (SOC) Care Trial Arm Participants With an Incorrect ED SOC Diagnosis
35
Participants with one or more PMEIs
Group
Value
95% CI
Standard of Care (SOC) Care Trial Arm Participants With a Correct ED SOC Diagnosis
1
Standard of Care (SOC) Care Trial Arm Participants With an Incorrect ED SOC Diagnosis
3
Expert VOG vs. ED SOC Six-Category Diagnosis Accuracy (Participants With a Known Final Diagnosis, One-arm Comparison [SOC Arm Only])Secondary· 30-day follow-up time point
Total diagnosis accuracy Expert VOG vs. ED SOC using 30-day adjudicated final diagnoses categorized in one of six diagnosis categories (3 peripheral, 1 central, 1 medical/other, 1 non-diagnosis). Expert VOG diagnoses were based on masked interpretation of ED index VOG tests in the context of basic demographic and medical history information from the ED index visit, while ED SOC diagnoses were based on all clinical information from the ED index visit, including neuroimaging and consultations. Final diagnoses were based on ED index visit, 1-week, and 30-day follow-up clinical assessments. The SO
Participants with a correct ED index visit diagnosis
Group
Value
95% CI
Expert VOG Diagnosis Within SOC Care Trial Arm
29
ED SOC Diagnosis Within SOC Care Trial Arm
13
Participants with an incorrect ED index visit diagnosis
Group
Value
95% CI
Expert VOG Diagnosis Within SOC Care Trial Arm
22
ED SOC Diagnosis Within SOC Care Trial Arm
38
VRT vs. ED SOC Stroke-No Stroke Diagnosis Accuracy (Primary Analysis-eligible Participants, Two-arm Comparison)Secondary· 30-day follow-up time point
Total diagnosis accuracy VRT vs. ED SOC using 30-day adjudicated final diagnoses categorized as stroke (any cerebrovascular event) versus no stroke (including peripheral vestibular, medical, psychiatric, or other central neurologic causes such as multiple sclerosis, traumatic brain injury, epilepsy, or anticonvulsant toxicity). "Index VRT Diagnosis" and "ED SOC Diagnosis" were compared to the "Adjudicated Final Diagnosis" based on ED index visit and 30-day follow-up clinical assessments.
Strokes: Participants with a correct ED index visit diagnosis
Group
Value
95% CI
VOG-guided Rapid Triage (VRT) Care
5
Standard of Care (SOC) Care
4
Strokes: Participants with an incorrect ED index visit diagnosis
Group
Value
95% CI
VOG-guided Rapid Triage (VRT) Care
3
Standard of Care (SOC) Care
2
Non-strokes: Participants with a correct ED index visit diagnosis
Group
Value
95% CI
VOG-guided Rapid Triage (VRT) Care
35
Standard of Care (SOC) Care
39
Non-strokes: Participants with an incorrect ED index visit diagnosis
Group
Value
95% CI
VOG-guided Rapid Triage (VRT) Care
11
Standard of Care (SOC) Care
1
Adverse events — posted to ClinicalTrials.gov
Time frame: Up to 30 days follow-up.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
VRT Care
Serious: 0/65 (0%)
Deaths: 0/65
Standard of Care (SOC)
Serious: 0/65 (0%)
Deaths: 0/65
Other adverse events (6 terms — click to expand)
Reaction
System
VRT Care
Standard of Care (SOC)
Transient increased dizziness, nausea, or vomiting during or immediately after VOG testing
Injury, poisoning and procedural complications
—
—
Transient discomfort where the goggles sit or mild headache during or immediately after VOG testing
Injury, poisoning and procedural complications
—
—
Transient fatigue or malaise during or immediately after VOG testing
Injury, poisoning and procedural complications
—
—
Persistent increase in dizziness, nausea, vomiting, or gait unsteadiness after VOG testing
Injury, poisoning and procedural complications
—
—
Transient neck discomfort during or immediately after VOG testing
Injury, poisoning and procedural complications
—
—
Mild skin irritation (including eyelid) from sticky eyepatch or goggles foam insert for VOG testing
AVERT is a randomized controlled trial comparing video-oculography (VOG)-guided care to standard care to assess accuracy of diagnoses and initial management decisions for emergency department (ED) patients with a chief symptom of vertigo or dizziness suspected to be of vestibular cause. The trial will test the hypothesis that VOG-guided rapid triage (VRT) will accurately, safely, and efficiently differentiate peripheral from central vestibular disorders in ED patients presenting acute vertigo or dizziness, and that doing so has the potential to improve post-treatment clinical outcomes for these patients.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07518069 — Genetic and Biohumoral Factors Involved in Menière's Disease and Their Correlation With Phenotypes
· recruiting
NCT07299487 — Diagnostic Aid for Vertigo Patients
· recruiting
NCT06738823 — Effect of Wii Fit Training in Comparison to Vestibular Rehabilitation Training on Balance in Patients With Benign Paroxy
· NA
· recruiting
NCT06321341 — Efficacy and Safety of Vespireit, Prolonged-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied
· Phase 4
· recruiting
NCT06062368 — Reducing Vertigo Associated With MRI Machines
· NA
· recruiting
Other Johns Hopkins University trials
Trials by the same sponsor.
NCT06236542 — Tracheostomy Robotics and Cutting-edge Health Education for Airway Safety
· NA
· not yet recruiting
NCT07532252 — Daridorexant for Alcohol Use Disorder
· Phase 2
· not yet recruiting
NCT06687655 — Impact of Exogenous Ketones on Sleep Apnea
· Phase 1, PHASE2
· not yet recruiting
NCT07079111 — 3D Printed Occlusal Splints for Intraoperative Use
· NA
· not yet recruiting
NCT02998502 — The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Johns Hopkins University
Last refreshed: 26 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02483429.